Melanoma Practice Review Issue 14
In this issue:
Clinical practice guideline on immunotherapy for melanoma
Durable clinical benefit to adjuvant mRNA vaccine in resected melanoma
Lifileucel approved in the US for post-PD-1 unresectable melanoma
Pre-treatment with fenofibrate may boost cell-based therapy in melanoma
Tebentafusp confers a durable survival benefit in HLA-A*02:01– positive uveal melanoma
Is tebentafusp superior to nivolumab + ipilimumab in metastatic uveal melanoma?
Emotional distress blunts response to neoadjuvant immunotherapy
PBS listings
FDA approves phase 3 testing of TLPO vaccine for melanoma
SEACRAFT-2 to assess naporafenib + trametinib for refractory NRAS-mutant disease
Real-world effectiveness of tebentafusp
Darovasertib + crizotinib promising for uveal melanoma
COVID-19 resources
Conferences, workshops and CPD
Expert contributor
Professor Peter Hersey
Peter Hersey is an honorary Professor of Immuno Oncology in the University of Sydney and a faculty member of the Melanoma Institute Australia. He has conducted a number of phase I to III trials of immunotherapy in melanoma, including use of modified peptide antigens and dendritic cell vaccines. He has taken a leading role in […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.